SEC Form 4 · accession 0001415889-18-000329
INNOVUS PHARMACEUTICALS, INC. · INNV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry Jemil Esber
Director
Period of report
Feb 23, 2018
Accepted (ET)
Feb 27, 2018 · 3:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411879
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Feb 23, 2018 | A | 71,856 | A | Feb 23, 2018 | Feb 23, 2028 | Common Stock | 71,856 | 2,099,231 | D |
| Restricted Stock UnitsF1,F4 | — | Feb 23, 2018 | A | 500,000 | A | — | Feb 23, 2028 | Common Stock | 500,000 | 2,599,231 | D |
Explanation of responses
- F1Each restricted stock unit represents the contingent right to receive, at settlement, one share of common stock.
- F2The Reporting Person was granted a Restricted Stock Unit on February 23, 2018 of 35,928 shares, which were fully vested on the date of the grant. The RSU is for the Reporting Person's quarterly compensation as a member of the Board of Directors for the fourth quarter of 2017 and was valued on December 31, 2017 in accordance with the approved compensation plan for the non-employee members of the Board of Directors.
- F3These restricted stock units were granted pursuant to the Issuer's Amended and Restated 2016 Equity Incentive Plan.
- F4RSU was granted on February 23, 2018. 125,000 RSUs vest on February 23, 2019; the total remaining shares vest in eight (8) pro rata equal installments, quarterly for two (2) years thereafter, subject to continued service.